Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23374138 | 1.00 | KDM4E (0.30) | KDM4EPKM | |
| SCHEMBL19920122 | 0.79 | — | — | |
| SCHEMBL23110417 | 0.78 | EPHX1 (0.31) | — | |
| SCHEMBL3414852 | 0.72 | — | — | |
| SCHEMBL23394192 | 0.72 | — | — | |
| SCHEMBL12899559 | 0.65 | — | — | |
| SCHEMBL11410719 | 0.65 | — | — | |
| SCHEMBL13811435 | 0.64 | — | — | |
| SCHEMBL13877874 | 0.64 | KDM4E (0.33) | KDM4EPKM | |
| SCHEMBL13877824 | 0.64 | KDM4E (0.33) | KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283319-A1 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS | Regulus Therapeutics Inc. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8110558-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAS | Regulus Therapeutics Inc. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20120029049-A1 | Antisense Modulation of Superoxide Dismutase 1, Soluble Expression | Isis Corporation (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110224277-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | REGULUS THERAPEUTICS, LLC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7897582-B2 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7696345-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7683036-B2 | especially nucleic acid and nucleic acid-like oligomers, which are targeted to or mimic nucleic acids comprising or encoding small non-coding RNAs, and which act to modulate the levels of small non-coding RNAs, or interfere with their function | Regulus Therapeutics Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | ISIS PHARMACEUTICALS, INC. | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | CD2BP2, MICA, CD74 | KDM4E 3752/4885PKM 4779/4885 |
| US-20120029049-A1 | Antisense Modulation of Superoxide Dismutase 1, Soluble Expression | SOD1, SOD3, RNASE1 | KDM4E 4721/4885PKM 4419/4885 |
| US-20070276139-A1 | Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis | RPP30, NOP10, NR0B1 | KDM4E 3836/4885PKM 3655/4885 |
| US-20120283319-A1 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS | SNRPE, NSUN2, NSUN3 | KDM4E 2043/4885PKM 2531/4885 |
| US-20110224277-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | SNRPE, NSUN2, NSUN3 | KDM4E 2043/4885PKM 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.